An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
Ono Pharmaceutical Co., Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histopathologic confirmation of the following tumor types (please refer to protocol for full details pertaining to eligible tumor types):
1. Merkel Cell Carcinoma
2. Gastric or Gastro-Esophageal junction carcinoma (No longer enrolling this tumor type)
3. Nasopharyngeal Carcinoma
4. Squamous cell carcinoma (SCC) of the cervix, vagina, or vulva
5. Squamous cell carcinoma of the Head and Neck
6. Squamous cell carcinoma of the anal canal and penis
7. Recurrent/metastatic SCC of the cervix not amenable to curative treatment with surgery and/or radiation therapy who are unsuitable for platinum-based therapy may enroll in the cervical cancer Combination B expansion cohort
Measurable disease by CT or MRI
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Patient willing to comply to provide tumor tissue (archival or fresh biopsy specimen)
Men and women of age 18 or older
You may not be if
Active brain metastases or leptomeningeal metastases
Patients with active, known or suspected autoimmune disease
Patients with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
Patients with hepatitis
Patients with HIV
Pregnant or breastfeeding women
Clareo Health | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
